Outlook of Diabetic Macular Edema – Current Landscape and the Way ForwardLONG-LASTING VEGF BLOCKERS, COMPOUNDS WITH VEGF- INDEPENDENT MECHANISM AND, TOPICAL AND ORAL TREATMENT OPTIONS, BRING THE QUEST FOR THE “IDEAL RETINAL DRUG” A STEP CLOSER�
SKU ID :MP-15927290 | Published Date: 03-Jul-2020 | No. of pages: 81Description
TOC
Table 1: NOVEL DME THERAPIES IN DEVELOPMENT AND UPCOMING
DEVELOPMENT MILESTONES
Table 2: TREATMENT OF DIABETIC MACULAR EDEMA IN THE US
Table 3: STUDIES OF ANTI-VEGF AGENTS AND CHANGE IN BCVA IN DME
PATIENTS
Table 4: STUDIES OF STERIOD AGENTS AND CHANGE IN BCVA IN DME
PATIENTS
Table 5: NEW TRIAMCINOLONE ACETONIDE (MAQAID) DETAILS
Table 6: INDIRECT COMAPRISON OF MAQAID WITH OTHER OPHTHALMIC
STERIODS FOR DME
Table 7: NOVEL DME THERAPIES IN DEVELOPMENT
Table 8: DME PIPELINE -PHASE III
Table 9: DME PIPELINE -PHASE II
Table 10: DME PIPELINE -PHASE I
Table 11: DME PIPELINE -PRE-CLINICAL
Tables & Figures
Figures 1: PROGRESSION OF DME
Figures 2: PATHOLOGY OF DME VISIBLE ON OCT IMAGING
Chart 1: NUMBER OF DME TREATED PATIENTS IN THE US (2014-2019)
Chart 2: US DME THERAPEUTIC MARKET SIZE IN 2019 AND 2025
Chart 3: US ANTI-VEGF THERAPEUTIC MARKET SIZE, 2014-2019
Chart 4: VALUE AND VOLUME SHARES OF CURRENT OPHTHALMIC ANTI-
VEGF’S IN THE US
Chart 5: US DME ANTI-VEGF THERAPEUTIC MARKET SIZE – 2019
Chart 6: US DME ANTI-VEGF THERAPEUTIC MARKET SIZE, 2020-2025
Chart 7: US DME-ANTI-VEGF OPHTHALMIC VALUE MARKET SHARE IN 2025
Chart 8: US STERIOD OPHTHALMIC MARKET SIZE BY VALUE, 2014-2019
Chart 9: US STERIOD OPHTHALMIC MARKET SIZE BY VOLUME, 2014-2019
Chart 10: US DME STERIODS THERAPEUTIC MARKET SIZE IN 2019 AND IN
2025
Companies
- PRICE
-
$4500$9500Buy Now